Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 135INDUSTRY 125NIH 7OTHER_GOV 3NETWORK 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 23Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 14Colorectal Neoplasms 12Lymphoma 10Neoplasms 9Lung Neoplasms 9Melanoma 8Leukemia, Myeloid, Acute 8Pancreatic Neoplasms 7Lymphoma, Non-Hodgkin 7Leukemia, Biphenotypic, Acute 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Ependymoma 5Endometrial Neoplasms 5Colonic Neoplasms 5Wilms Tumor 4Rectal Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Neoplasm Metastasis 4Medulloblastoma 4Malignant Solid Neoplasm 4Lymphoma, Mantle-Cell 4

Interventions

zanubrutinib 1Immunotherapy, Adoptive 1Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Recurrence × 90 days × Clear all
NCT01790152 2026-05-18

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Children's Oncology Group

Recruiting
420 enrolled
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Recurrence, Osteosarcoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07341191 2026-05-14

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Canadian Cancer Trials Group

Phase 2 Recruiting
40 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡